MedTrace Logo

The Effects of Amiloride and Spironolactone on Renophysiological and Cardiovascular Variables

NCT01195805 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2015-08-20

No results posted yet for this study

Summary

The investigators wish to study the effect of retaining potassium. The participants have essential hypertension. The test substances are Amiloride, Spironolactone and placebo. The participants will ingest tablets for 28 days before being examined. We will perform a 24 hours urine collection, 24-hours bloodpressure measurement, blood and urine samples and we also examine the patient using a SphygmoCor.

Conditions

  • Essential Hypertension

Interventions

DRUG

Spironolactone

1 tablet twice a day for 28 days

OTHER

Placebo

1 tablet twice a day for 28 days

DRUG

Amiloride

1 tablet twice a day for 28 days

Sponsors & Collaborators

  • Regional Hospital Holstebro

    lead OTHER

Principal Investigators

  • Solveig K Matthesen, MD · Departments of medical research and medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
40 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-08-31
Primary Completion
2015-08-31
Completion
2015-08-31

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01195805 on ClinicalTrials.gov